Overview

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2025-03-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.

Phase:

Phase 3

Details

Lead Sponsor:

Exelixis

Treatments:

Ipilimumab
Nivolumab